MENU
BLFS
AS OF
Feb 3, 04:59 PM (EDT)
Price
$22.87
Change
-$4.58 (-16.68%)
Capitalization
1.08B
37 days until earnings call
Intraday BUY SELL Signals
+Compare
BLFS
Stock ticker: NASDAQ
AS OF
Feb 3, 04:59 PM (EDT)
Price
$22.87
Change
-$4.58 (-16.68%)
Capitalization
1.08B

BLFS stock forecast, quote, news & analysis

BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry... Show more

BLFS
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. BLFS showed earnings on November 06, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for BLFS with price predictions
Feb 02, 2026

BLFS's RSI Oscillator ascending out of oversold territory

The RSI Indicator for BLFS moved out of oversold territory on February 02, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In of the 24 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BLFS advanced for three days, in of 306 cases, the price rose further within the following month. The odds of a continued upward trend are .

BLFS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BLFS as a result. In of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BLFS turned negative on January 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .

BLFS moved below its 50-day moving average on January 23, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLFS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BLFS entered a downward trend on January 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BLFS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.040) is normal, around the industry mean (11.444). P/E Ratio (0.000) is within average values for comparable stocks, (149.532). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.462). BLFS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (10.571) is also within normal values, averaging (110.694).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 11.42B. The market cap for tickers in the group ranges from 246 to 176.09B. ISRG holds the highest valuation in this group at 176.09B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -2%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 25%. TUTH experienced the highest price growth at 107%, while GCTK experienced the biggest fall at -42%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 9%. For the same stocks of the Industry, the average monthly volume growth was 16% and the average quarterly volume growth was -11%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 67
Price Growth Rating: 61
SMR Rating: 78
Profit Risk Rating: 94
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
BLFS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a manufacturer of proprietary and generic bio preservation media products for cells, tissues and organs

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
3303 Monte Villa Parkway
Phone
+1 425 402-1400
Employees
414
Web
https://www.biolifesolutions.com